SOPHiA GENETICS (SOPH) and AstraZeneca Spain (AZN) Commit to Increasing Ovarian Cancer Testing in Spain

Go back to SOPHiA GENETICS (SOPH) and AstraZeneca Spain (AZN) Commit to Increasing Ovarian Cancer Testing in Spain

SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain

February 7, 2024 6:51 AM EST

SOPHiA GENETICS and AstraZeneca Spain expand HRD testing program to support molecular diagnosis of ovarian cancer in Spain

BOSTON and ROLLE, Switzerland and MADRID, Feb. 7, 2024 /PRNewswire/ -- SOPHiA... More